Oral Peptides Explained: Why Tablets Are Difficult

A tablet looks simpler than an injection, but for peptide medicines the biology is usually working against the oral route. A swallowed peptide has to survive the stomach and intestine, remain chemically intact, reach an absorptive surface and then cross a cellular barrier before enough active material reaches the bloodstream.

That combination is difficult. Most peptide medicines therefore use injections or other delivery systems rather than ordinary tablets. The small number of successful oral peptide products are useful because they show what has to be solved before a peptide can work reliably by mouth.

What does oral bioavailability mean?

Bioavailability describes how much of a medicine reaches the systemic circulation in an active form after it is given.

For an injected medicine, the route can bypass much of the digestive system. An oral medicine has a longer path. It must remain intact in the gastrointestinal tract and then cross an epithelial barrier before entering the circulation.

For peptides, those two stages are both difficult. Proteolytic enzymes are designed to break peptide bonds, while intact peptides are generally much larger and more water soluble than the small molecules that readily pass through cell membranes.

This is different from peptide half life. Half life describes how quickly a compound is removed once it is in the body. Oral bioavailability asks how much of the swallowed compound gets into the body in the first place.

Why does the digestive tract make peptide delivery difficult?

Peptides are chains of amino acids. The digestive system is specifically equipped to break dietary proteins and peptides into smaller fragments that can be absorbed as nutrients.

That creates a stability problem before absorption even begins. A therapeutic peptide that is exposed to acid and proteolytic enzymes may be cleaved into fragments before enough intact molecule reaches an absorptive surface.

The second problem is permeability. The epithelial cells lining the stomach and intestine form a controlled barrier. Small lipophilic molecules can often cross cell membranes more readily than larger hydrophilic peptides. Intact peptide molecules therefore tend to cross inefficiently.

A translational study of oral semaglutide described these same barriers when testing how a peptide could be absorbed from a tablet. The investigators reported that poor gastrointestinal absorption and proteolytic degradation are central obstacles to oral peptide delivery Mechanistic ¹.

The result is simple: putting a peptide into a capsule does not remove the biological barriers that made injection necessary in the first place.

How did oral semaglutide get around some of those barriers?

Oral semaglutide is useful as a worked example because semaglutide is a peptide, yet licensed tablet formulations exist.

The tablet is not simply semaglutide pressed into a conventional pill. It is coformulated with salcaprozate sodium, also known as SNAC, an absorption enhancer.

In a mechanistic study using clinical data and preclinical models, semaglutide absorption was found to occur mainly in the stomach, close to the tablet surface. The study found that SNAC created local conditions that reduced degradation and transiently increased transcellular absorption of semaglutide Mechanistic ¹.

That matters because it shows that oral delivery is a formulation problem as much as a molecule problem. The active peptide and the absorption technology work together.

The current UK Rybelsus Summary of Product Characteristics states that salcaprozate sodium facilitates semaglutide absorption and that absorption predominantly occurs in the stomach Regulator approved indication ².

Even a successful oral peptide can have low bioavailability

An oral peptide does not need most of the swallowed dose to reach the circulation in order to be clinically useful. It needs exposure that is sufficient, predictable enough and supported by clinical evidence.

The current Rybelsus product information estimates absolute oral bioavailability at about 1% to 2% and describes high variability between people Regulator approved indication ².

The newer oral Wegovy formulation licensed in the UK for weight management also uses salcaprozate sodium. Its product information estimates absolute bioavailability at roughly 1% to 2% after oral administration Regulator approved indication ³.

Those figures are a useful reality check. A successful tablet does not mean the digestive barriers disappeared. It means the formulation can produce enough reproducible exposure for a medicine to be developed, tested and licensed.

Why does the stomach matter for oral semaglutide?

Small molecule tablets are often discussed as if absorption mainly happens after the drug reaches the intestine. Oral semaglutide behaves differently.

A pharmacoscintigraphic study followed tablet erosion and drug exposure in 26 healthy men. Complete tablet erosion occurred in the stomach. Longer time to complete erosion and later gastric emptying were associated with greater semaglutide exposure Human ⁴.

That supports the mechanism seen in the earlier translational work: the tablet creates a local environment in the stomach where absorption becomes possible.

It also explains why the formulation cannot be treated as interchangeable with loose peptide powder, a different capsule or a home made mixture. Changing the dosage form can change where the peptide is released, what it is exposed to and whether an absorption enhancer is present at the right place and time.

Food and formulation conditions can change exposure

A separate human pharmacokinetic programme tested how oral semaglutide exposure changed under different administration conditions. In the food effect trial, 78 healthy participants were randomised to fed or fasting conditions. Limited or no measurable semaglutide exposure was seen in the fed arm, while measurable exposure was found in the fasting arms Human ⁵.

The purpose of mentioning this is not to provide instructions for taking a medicine. It shows how sensitive oral peptide absorption can be to the surrounding conditions.

For licensed products, the correct administration instructions belong in the official product information and should be followed exactly. They cannot be generalised to other peptides.

Does low oral bioavailability mean the medicine cannot work?

No. Bioavailability and clinical efficacy are connected, but they are not the same measurement.

PIONEER 1 randomised 703 adults with type 2 diabetes to oral semaglutide or placebo for 26 weeks. Oral semaglutide produced greater reductions in HbA1c than placebo across the studied groups, showing that a peptide with low oral bioavailability can still produce clinically meaningful exposure when the formulation and treatment programme have been validated in controlled trials Human ⁶.

The lesson is not that low absorption is unimportant. It is that a medicine is judged by the exposure and clinical effect achieved by the finished formulation, not by the percentage absorbed in isolation.

Why can one peptide work orally while another cannot?

There is no single rule based only on molecular size or peptide length.

Several factors can matter:

resistance to chemical and enzymatic degradation;
the peptide's charge, polarity and shape;
how readily it crosses a biological membrane;
where the dosage form releases the peptide;
whether a formulation protects the peptide locally;
whether an absorption enhancer changes the immediate environment;
how variable absorption is between people.

That means two peptide molecules can behave very differently after oral administration. It also means success with oral semaglutide cannot be transferred automatically to BPC-157, TB-500, CJC-1295, retatrutide or another peptide.

Each molecule and formulation needs its own evidence.

What changed in the UK in 2026?

The UK now has a particularly clear example of oral peptide delivery moving beyond diabetes treatment.

On 11 June 2026, the MHRA approved the first GLP-1 receptor agonist tablet for weight loss and weight management in the UK, a semaglutide tablet marketed as Wegovy Regulator approved indication ⁷.

The MHRA also lists Rybelsus as a licensed semaglutide medicine for type 2 diabetes Regulator approved indication ⁸.

These approvals demonstrate that peptide tablets are possible. They do not demonstrate that peptides in general are orally active.

Why an unlicensed oral peptide is a different question

A licensed oral peptide medicine is a complete pharmaceutical product. Its active ingredient, excipients, manufacturing process, release behaviour, pharmacokinetics, stability and clinical performance have been assessed as part of that product.

An unlicensed capsule containing a peptide name on the label does not inherit the evidence of a licensed formulation.

Under regulation 46 of the Human Medicines Regulations 2012, medicinal products generally require appropriate authorisation for sale or supply in the UK, subject to the specific exceptions set out in the Regulations ⁹.

That distinction matters when people see claims that an injectable research peptide can simply be made "oral". The scientific question is not whether the peptide can physically be swallowed. It is whether intact active material reaches the circulation at a defined and validated exposure.

What about capsules, coatings and absorption enhancers?

Drug developers use several strategies to improve oral delivery. These can include protecting the peptide from local degradation, controlling where a dosage form releases its contents and using excipients that alter local absorption.

The important point is that these are formulation technologies, not generic tricks that work for every peptide.

The semaglutide studies show that even the location of tablet erosion in the stomach can be linked to systemic exposure. That level of formulation dependence is why a licensed dosage form cannot be reverse engineered conceptually from the active peptide alone.

BioRx explains how peptide medicines are manufactured in How Peptides Are Made. The quality question is also different from absorption: a vial can contain the correct peptide and still be unsuitable for oral delivery, while an oral formulation can be chemically correct but fail if exposure is too low or too variable.

Oral bioavailability versus stability and half life

Three related ideas are often mixed together.

Stability before absorption asks whether the peptide stays intact in the gastrointestinal environment.

Bioavailability asks how much intact active material reaches the circulation.

Half life asks how long the compound remains in the body after it has reached the circulation.

A peptide can have a long systemic half life and still have poor oral bioavailability. Semaglutide is a good example: its long persistence in the body does not remove the need for a specialist oral absorption system.

For the wider pharmacokinetic picture, see Peptide Half Life Explained.

What should a reader take from this?

Most peptides are difficult to deliver as ordinary tablets because the gastrointestinal tract presents both a degradation barrier and an absorption barrier.

Oral semaglutide demonstrates that those barriers can sometimes be engineered around. Its success depends on a specific coformulation, local gastric absorption, controlled product design and human clinical validation. Even then, absolute oral bioavailability remains low and variable.

The practical conclusion is scientific rather than instructional: route of administration is part of the medicine. Evidence for an injected peptide does not prove that an oral version works, and evidence for one licensed oral peptide formulation does not transfer to another molecule or an unlicensed product.

For the broader basics, start with What Are Peptides?.

Frequently asked questions

Can peptides be absorbed through the stomach?

Some can under the right formulation conditions. Oral semaglutide is absorbed predominantly in the stomach when coformulated with salcaprozate sodium. That is a product specific finding, not a general rule for all peptides Mechanistic.

Why are most peptide medicines injected?

Injection bypasses the digestive enzymes and epithelial absorption barriers that make intact peptide delivery by mouth difficult.

Does putting a peptide into a capsule make it orally active?

No. A capsule changes the dosage form, but it does not by itself solve degradation, permeability or exposure problems.

Is oral semaglutide well absorbed?

Its UK product information describes low absolute bioavailability, roughly 1% to 2% for both the current Rybelsus formulation and the current oral Wegovy formulation, with variable absorption Regulator approved indication.

Are oral peptides now common?

No. Licensed oral peptide medicines remain unusual compared with injected peptide medicines. The existence of oral semaglutide shows what specialist formulation can achieve, rather than showing that the oral route is easy for peptides.

References

Studies marked "View study in BioRx" sit in the clinical studies index with their design and evidence grade.

Oral Peptides Explained: Why Most Peptides Are Hard to Turn Into Tablets